LNC Therapeutics raises €6.5m to reinforce its R&D in the microbiota field

47e64bcf-896e-4bc0-b4db-413992dc9498articleimage.jpg

29 Sep 2017 --- LNC Therapeutics, a company specialized in the research and development of gut microbiota directed drugs for the treatment of obesity and associated cardiometabolic diseases, has raised a €6.5 million (US$7.67 million) Series C funding round. This new round, co-led by Seventure Partners, brings together a consortium of investors and a family office. Additionally, the company has appointed a new chief scientific officer, Dr. Sandrine Claus, to lead the gut microbiota project.

“This funding round of €6.5 million establishes LNC Therapeutics as a key player in the treatment of obesity and metabolic disorders through an action on the gut microbiota,” explains Jean-Luc Treillou, LNC therapeutics’ CEO. 

“Our recent clinical trial on obese patients indicated that visceral fat loss in this population was correlated with a modulation of the gut microbiota, specifically with a bacterial family known for its anti-obesity potential,” Treillou adds.

“Hence, our current objective is to develop new drug candidates whose mechanism of action requires interaction with the gut microbiota and the intestinal membrane. Targeted therapeutic indications include pathologies caused by excessive visceral fat accumulation and chronic inflammation such as obesity and NASH.”

“The presentation of our development plan is scheduled in the first quarter of 2018 and will include targets and project milestones,” Caroline Bernard, Strategic Development Project Manager at LNC Therapeutics, tells NutritionInsight.

Regarding the populations LNC Therapeutics intends to target its research on, Bernard adds that LNC will indeed focus on some specific (but still large) sub-populations to maximize clinical outcomes, but did not provide further details on these sub-populations.

Click to EnlargeNew CSO
Newly appointed Chief Scientific Officer Sandrine Claus, Ph.D., is Associate Professor in Integrative Metabolism at the University of Reading, which she joined in 2010. Its research focuses on the host-gut microbial metabolic interactions to link gut microbial ecology to metabolic health.

Claus’ mission within LNC Therapeutics will be leading the ambitious R&D pipeline and the development of new treatments in the field of cardiometabolic diseases and other fields of investigation relating to the bioactivity of some peptides.

“It is with great pleasure that I am joining LNC Therapeutics and its dynamic team. It is an exciting time to join a company which owns a large pipeline of innovative patents related to gut microbiota activity, aimed at improving health outcomes,” comments Sandrine Claus.

“Our new CSO, Dr. Sandrine Claus, Ph.D., who is an expert on the role of gut microbiota in the development of metabolic disorders, is a strategic recruitment. Our strategic plan now has to be delivered and will drive us to an IPO by the end of 2019,” concludes Jean-Luc Treillou.

“We are pleased to participate in this new round and to have syndicated the Series C with other ‘deep pocket’ investors. LNC Therapeutics, a company we have supported since the Series A, chose to remain discreet over the last two years in the booming universe of the microbiome, to gain a foothold and consolidate its competitive position. LNC Therapeutics is complementing our portfolio of microbiome champions, consisting of companies that are advanced in their research,” adds Isabelle de Crémoux, CEO of Seventure Partners and founder of Health For Life Capital.

By Lucy Gunn

Related Articles

Nutrition & Health News

Herbal extracts (Part 1): Taking value from herbs – Challenges, delivery systems and meeting trends

22 Jan 2018 --- With the popularity of traditional medicine and naturalness, in general, experiencing something a resurgence of late, it is instructive to look at the general space around herbal extracts.

Nutrition & Health News

Bile acids increase fat burning, offering a potential new treatment for obesity

16 Jan 2018 --- A specific group of bile acids could directly burn away the lipids in our fat depots, effectively making it a new therapy against obesity. This is according to a new study led by the lab Kristina Schoonjans at EPFL. Current treatments for obesity try to decrease calorie intake and increase energy expenditure, but the problem is maintaining long-term effects. Non-invasive treatments, like diets and drugs that reduce intestinal ingestion, are widely unpopular among patients, while bariatric surgery seems to be the only reliable treatment for obese people, despite being both expensive and invasive.

Nutrition & Health News

Cruciferous vegetables and probiotic combination: New allies in fight against bowel cancer

15 Jan 2018 --- A team of researchers in the National University Singapore (NUS) Medicine lab of Associate Professor Matthew Chang have found a way to turn a mix of bacteria and vegetables into a targeted system that seeks out and kills colorectal cancer cells. According to the researchers, this combination could be used in the prevention of colorectal cancer – one of the most common cancers in the world – and to clean up the cancer cells remaining after surgical removal of tumors, through a sustainable, low-cost therapeutic regimen.

Nutrition & Health News

Estrogen-mimicking compounds in foods may decrease effectiveness of breast cancer treatment

12 Jan 2018 --- Two estrogen-mimicking compounds found in many foods appear to potently reverse the effects of palbociclib/letrozole, a popular drug combination for treating breast cancer, according to research by scientists from The Scripps Research Institute (TSRI). Their study, published in the journal Cell Chemical Biology, suggests that exposure to chemical compounds called xenoestrogens may significantly reduce the effectiveness of anti-estrogen treatments for cancer.

Nutrition & Health News

Maritech fucoidans gain European novel foods status

10 Jan 2018 --- Marinova’s Maritech fucoidan extracts have gained novel foods status in the EU. Extracted from Undaria pinnatifida and Fucus vesiculosus seaweed, these bioactive marine ingredients mark the first fucoidans to receive approval as novel foods. The official approval notice was issued by the Superior Health Council of Belgium on 5 December, 2017, making Maritech fucoidans the only fucoidan ingredients with global regulatory acceptance. This includes FDA notified GRAS in the USA, TGA listable ingredients in Australia, NHP listed in Canada, KFDA registered in Korea and now novel foods status in Europe, Claire Smoorenburg, Marketing & Communications Officer at Marinova, tells NutritionInsight.

More Articles
URL : http://www.nutritioninsight.com:80/news/lnc-therapeutics-raises-65m-to-reinforce-its-rd-in-the-microbiota-field.html